The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Open accessAbstract
Purpose: To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome. Patients and Methods: Consecutive BRAF-tested Australian patients with metastatic melanoma (n = 197) were observed prospectively. A comprehensive range of clinicopathologic variables were correlated with BRAF mutation status, and a survival analysis was conducted. Results: Forty-eight percent of patients had a BRAF mutation; 70 patients (74%) had V600E, 19 (20%) had V600K, and six (6%) had other genotypes. Other than age at diagnosis of distant metastasis (median age, 56 v 63 years for BRAF-mutant v BRAF wild-type patients, respectively; P < .001), there was no significant difference in clinical features of patients with metastatic melanoma by mutation status. Features of the antecedent primary melanoma significantly associated with a BRAF mutation (P < .05) were histopathologic subtype, presence of mitoses, single or occult primary melanoma, truncal location, and age at diagnosis of primary tumor ≤ 50 years. The interval from diagnosis of first-ever melanoma to distant metastasis was not significantly different between BRAF-mutant and BRAF wild-type patients; however, the median survival of patients with newly diagnosed metastatic melanoma was 5.7 months for BRAF-mutant patients not treated with a BRAF inhibitor, 8.5 months for BRAF wild-type patients, and not reached for BRAF-mutant patients treated with a BRAF inhibitor. Conclusion: V600K mutations comprised 20% of BRAF mutations. Characteristics of the antecedent primary melanoma and age at diagnosis differed in BRAF-mutant and BRAF wild-type patients. The presence of mutant BRAF had no impact on the disease-free interval from diagnosis of first-ever melanoma to first distant metastasis; however, it may have impacted survival thereafter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Determinants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664
Improving Melanoma Classification by Integrating Genetic and Morphologic Features
Viros, A., Fridlyand, J., Bauer, J., Lasithiotakis, K., Garbe, C., Pinkel, D., & Bastian, B. C. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050120 · Cited by 379
MC1R Germline Variants Confer Risk for BRAF -Mutant Melanoma
Landi, M. T., Bauer, J., Pfeiffer, R. M., Elder, D. E., Hulley, B., Minghetti, P., Calista, D., Kanetsky, P. A., Pinkel, D., & Bastian, B. C. (2006) · Science · doi:10.1126/science.1127515 · Cited by 346
Houben, R., Becker, J. C., Kappel, A., Terheyden, P. A. M., Bröcker, E., Goetz, R., & Rapp, U. R. (2004) · Journal of Carcinogenesis · doi:10.1186/1477-3163-3-6 · Cited by 325
Edlundh-Rose, E., Egyha??zi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., & Lundeberg, J. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232300.22032.86 · Cited by 318
Jönsson, G., Busch, C., Knappskog, S., Geisler, J., Miletic, H., Ringnér, M., Lillehaug, J. R., Borg, Å., & Lønning, P. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2509 · Cited by 283
Kefford, R., Arkenau, H., Brown, M. P., Millward, M., Infante, J. R., Long, G. V., Ouellet, D., Curtis, M., Lebowitz, P. F., & Falchook, G. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8503 · Cited by 275
Self-citationRubinstein, J. C., Sznol, M., Pavlick, A. C., Ariyan, S., Cheng, E., Bacchiocchi, A., Kluger, H. M., Narayan, D., & Halaban, R. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-67 · Cited by 254
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A. N., BUSAM, K. J., & Polsky, D. (2003) · PubMed · Cited by 212
Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas
Shinozaki, M., Fujimoto, A., Morton, D. L., & Hoon, D. S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1169-3 · Cited by 212
BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar, R., Angelini, S., Czene, K., Sauroja, I., Hahka‐Kemppinen, M., Pyrhönen, S. O., & Hemminki, K. (2003) · PubMed · Cited by 205
Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma
Thomas, N. E., Edmiston, S. N., Alexander, A., Millikan, R. C., Groben, P. A., Hao, H., Tolbert, D., Berwick, M., Busam, K., Begg, C. B., et al. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-1038 · Cited by 192
Liu, W., Kelly, J. W., Trivett, M., Murray, W. K., Dowling, J. P., Wolfe, R., Mason, G., Magee, J., Angel, C., Dobrovic, A., et al. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700632 · Cited by 188
Ugurel, S., Thirumaran, R. K., Bloethner, S., Gast, A., Sucker, A., Mueller-Berghaus, J., Rittgen, W., Hemminki, K., Becker, J. C., Kumar, R., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000236 · Cited by 134
Murali, R., Desilva, C., Thompson, J. F., & Scolyer, R. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.9567 · Cited by 119
Self-citationAkslen, L. A., Angelini, S., Straume, O., Bachmann, I. M., Molven, A., Hemminki, K., & Kumar, R. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23788.x · Cited by 111
Hacker, E., Hayward, N. K., Dumenil, T. D., James, M. R., & Whiteman, D. C. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.182 · Cited by 93
Wu, J. M., Rosenbaum, E., Begum, S., & Westra, W. H. (2007) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e3181584950 · Cited by 75
Clinical significance of BRAF mutations in metastatic melanoma
Chang, D. Z., Panageas, K. S., Osman, I., Polsky, D., BUSAM, K. J., & Chapman, P. B. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-46 · Cited by 65
Roth, A., Klingbiel, D., Yan, P., Fiocca, R., Delorenzi, M., Labianca, R., Cunningham, D., Cutsem, E. V., Bosman, F. T., & Tejpar, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3504 · Cited by 53
Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas
Kannengiesser, C., Spatz, A., Michiels, S., Eychène, A., Dessen, P., Lazar, V., Winnepenninckx, V. J. L., Lesueur, F., Druillennec, S., Robert, C., et al. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.01.002 · Cited by 50
Gallagher, S. J., Thompson, J. F., Indsto, J. O., Scurr, L. L., Lett, M., Gao, B.-F., Dunleavey, R., Mann, G. J., Kefford, R. F., & Rizos, H. (2008) · Neoplasia · doi:10.1593/neo.08702 · Cited by 48
Self-citationdi Ciccone, B. L., Brown, R., Gueguen, J. A., Bylund, C. L., & Kissane, D. W. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp289 · Cited by 28
Kirschner, M., Helmke, B. M., Starz, H., Benner, A., Thome, M., & Deichmann, M. (2005) · Melanoma Research · doi:10.1097/00008390-200510000-00011 · Cited by 20
Cited by
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
Self-citationSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationSmall molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Metadata
- Authors
- Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, T. M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-04-01
- Volume
- 29
- Issue
- 10
- Pages
- 1239-1246
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2135925159
- Cited by
- 1,042
- References
- 29
- FWCI
- 38.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.